88 related articles for article (PubMed ID: 19554630)
21. Interrogating androgen receptor function in recurrent prostate cancer.
Zhang L; Johnson M; Le KH; Sato M; Ilagan R; Iyer M; Gambhir SS; Wu L; Carey M
Cancer Res; 2003 Aug; 63(15):4552-60. PubMed ID: 12907631
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice.
Wallner L; Dai J; Escara-Wilke J; Zhang J; Yao Z; Lu Y; Trikha M; Nemeth JA; Zaki MH; Keller ET
Cancer Res; 2006 Mar; 66(6):3087-95. PubMed ID: 16540658
[TBL] [Abstract][Full Text] [Related]
23. Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy.
Wikström P; Lindahl C; Bergh A
Prostate; 2005 Feb; 62(2):148-64. PubMed ID: 15389804
[TBL] [Abstract][Full Text] [Related]
24. A stroma targeted therapy enhances castration effects in a transplantable rat prostate cancer model.
Johansson A; Jones J; Pietras K; Kilter S; Skytt A; Rudolfsson SH; Bergh A
Prostate; 2007 Nov; 67(15):1664-76. PubMed ID: 17854058
[TBL] [Abstract][Full Text] [Related]
25. Mouse prostate cancer cell lines established from primary and postcastration recurrent tumors.
Liao CP; Liang M; Cohen MB; Flesken-Nikitin A; Jeong JH; Nikitin AY; Roy-Burman P
Horm Cancer; 2010 Feb; 1(1):44-54. PubMed ID: 20631921
[TBL] [Abstract][Full Text] [Related]
26. Androgen receptor up-regulates insulin-like growth factor binding protein-5 (IGFBP-5) expression in a human prostate cancer xenograft.
Gregory CW; Kim D; Ye P; D'Ercole AJ; Pretlow TG; Mohler JL; French FS
Endocrinology; 1999 May; 140(5):2372-81. PubMed ID: 10218991
[TBL] [Abstract][Full Text] [Related]
27. Cell proliferation and apoptosis during prostatic tumor xenograft involution and regrowth after castration.
Bladou F; Vessella RL; Buhler KR; Ellis WJ; True LD; Lange PH
Int J Cancer; 1996 Sep; 67(6):785-90. PubMed ID: 8824549
[TBL] [Abstract][Full Text] [Related]
28. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.
Gleave ME; Hsieh JT; Wu HC; von Eschenbach AC; Chung LW
Cancer Res; 1992 Mar; 52(6):1598-605. PubMed ID: 1371718
[TBL] [Abstract][Full Text] [Related]
29. Androgen receptor action in hormone-dependent and recurrent prostate cancer.
Agoulnik IU; Weigel NL
J Cell Biochem; 2006 Oct; 99(2):362-72. PubMed ID: 16619264
[TBL] [Abstract][Full Text] [Related]
30. Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin.
Hadaschik BA; Ettinger S; Sowery RD; Zoubeidi A; Andersen RJ; Roberge M; Gleave ME
Int J Cancer; 2008 May; 122(10):2368-76. PubMed ID: 18240145
[TBL] [Abstract][Full Text] [Related]
31. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.
Berenguer C; Boudouresque F; Dussert C; Daniel L; Muracciole X; Grino M; Rossi D; Mabrouk K; Figarella-Branger D; Martin PM; Ouafik L
Oncogene; 2008 Jan; 27(4):506-18. PubMed ID: 17637748
[TBL] [Abstract][Full Text] [Related]
32. The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer.
Fizazi K; Martinez LA; Sikes CR; Johnston DA; Stephens LC; McDonnell TJ; Logothetis CJ; Trapman J; Pisters LL; Ordoñez NG; Troncoso P; Navone NM
Clin Cancer Res; 2002 Mar; 8(3):775-81. PubMed ID: 11895908
[TBL] [Abstract][Full Text] [Related]
33. An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer.
Plymate SR; Haugk K; Coleman I; Woodke L; Vessella R; Nelson P; Montgomery RB; Ludwig DL; Wu JD
Clin Cancer Res; 2007 Nov; 13(21):6429-39. PubMed ID: 17975155
[TBL] [Abstract][Full Text] [Related]
34. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
35. Impact of the tumor microenvironment on host infiltrating cells and the efficacy of flt3-ligand combination immunotherapy evaluated in a treatment model of mouse prostate cancer.
Ciavarra RP; Brown RR; Holterman DA; Garrett M; Glass WF; Wright GL; Schellhammer PF; Somers KD
Cancer Immunol Immunother; 2003 Sep; 52(9):535-45. PubMed ID: 14627125
[TBL] [Abstract][Full Text] [Related]
36. Regulation of androgen receptor expression in the human heterotransplantable prostate carcinoma PC-82.
Ruizeveld de Winter JA; van Weerden WM; Faber PW; van Steenbrugge GJ; Trapman J; Brinkmann AO; van der Kwast TH
Endocrinology; 1992 Dec; 131(6):3045-50. PubMed ID: 1446639
[TBL] [Abstract][Full Text] [Related]
37. Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model.
Knuuttila M; Yatkin E; Kallio J; Savolainen S; Laajala TD; Aittokallio T; Oksala R; Häkkinen M; Keski-Rahkonen P; Auriola S; Poutanen M; Mäkelä S
Am J Pathol; 2014 Aug; 184(8):2163-73. PubMed ID: 24949550
[TBL] [Abstract][Full Text] [Related]
38. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients.
Gannon PO; Poisson AO; Delvoye N; Lapointe R; Mes-Masson AM; Saad F
J Immunol Methods; 2009 Aug; 348(1-2):9-17. PubMed ID: 19552894
[TBL] [Abstract][Full Text] [Related]
39. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy.
Sun Y; Wang BE; Leong KG; Yue P; Li L; Jhunjhunwala S; Chen D; Seo K; Modrusan Z; Gao WQ; Settleman J; Johnson L
Cancer Res; 2012 Jan; 72(2):527-36. PubMed ID: 22108827
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of Fn14 promotes androgen-independent prostate cancer progression through MMP-9 and correlates with poor treatment outcome.
Huang M; Narita S; Tsuchiya N; Ma Z; Numakura K; Obara T; Tsuruta H; Saito M; Inoue T; Horikawa Y; Satoh S; Habuchi T
Carcinogenesis; 2011 Nov; 32(11):1589-96. PubMed ID: 21828059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]